A key challenge of this study is that the decreased ANXA3 levels in MDD parallel the findings in schizophrenia and bipolar disorder, suggesting its potential as a cross-diagnostic biomarker for these disorders. The gene discussed is ANXA3; the disease is schizophrenia.